摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-异丙基苯基)乙酸乙酯 | 69574-21-6

中文名称
2-(3-异丙基苯基)乙酸乙酯
中文别名
——
英文名称
ethyl 2-(3-isopropylphenyl)acetate
英文别名
m-Isopropyl-phenylessigsaeure-ethylester;m-Cumylessigsaeureaethylester;Ethyl 2-(3-propan-2-ylphenyl)acetate
2-(3-异丙基苯基)乙酸乙酯化学式
CAS
69574-21-6
化学式
C13H18O2
mdl
——
分子量
206.285
InChiKey
HYROIMAIHKDALB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    270.3±9.0 °C(Predicted)
  • 密度:
    0.987±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    15
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(3-异丙基苯基)乙酸乙酯 在 lithium aluminium tetrahydride 作用下, 生成 3-异丙基苯乙醇
    参考文献:
    名称:
    树脂酸的合成研究—Ⅴ:脱氢松香酸的三种异构体的合成
    摘要:
    已经描述了三种脱氢松香酸的立体异构体的合成,并且它们与由Stork合成的异构体一起构成了整个系列,理论上是可能的。这些异构体的立体化学已被置于牢固的基础上。
    DOI:
    10.1016/s0040-4020(01)99353-6
  • 作为产物:
    描述:
    3-溴苯乙酸乙酯 在 palladium 10% on activated carbon 、 氢气 、 palladium diacetate 、 caesium carbonate2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下, 以 乙醇甲苯 为溶剂, 20.0~100.0 ℃ 、101.33 kPa 条件下, 反应 2.25h, 生成 2-(3-异丙基苯基)乙酸乙酯
    参考文献:
    名称:
    Optimization of Potent and Selective Quinazolinediones: Inhibitors of Respiratory Syncytial Virus That Block RNA-Dependent RNA-Polymerase Complex Activity
    摘要:
    A quinazolinedione-derived screening hit 2 was discovered with cellular antiviral activity against respiratory syncytial virus (CPE EC50 = 2.1 mu M), moderate efficacy in reducing viral progeny (4.2 log at 10 mu M), and marginal cytotoxic liability (selectivity index, SI similar to 24). Scaffold optimization delivered analogs with improved potency and selectivity profiles. Most notable were compounds 15 and 19 (EC50 = 300-500 nM, CC50 > 50 mu M, SI > 100), which significantly reduced viral titer (>400,000-fold), and several analogs were shown to block the activity of the RNA-dependent RNA-polymerase complex of RSV.
    DOI:
    10.1021/jm500902x
点击查看最新优质反应信息

文献信息

  • [EN] SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK<br/>[FR] SALICYLAMIDES DE SPIROHEPTANE ET COMPOSÉS ASSOCIÉS UTILISÉS COMME INHIBITEURS DE ROCK
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2017123860A1
    公开(公告)日:2017-07-20
    The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    本发明提供了式(I)的化合物:或立体异构体、互变异构体或药用可接受的盐,其中所有变量如本文所述定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用同一化合物治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
  • N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES
    申请人:Salvati Mark E.
    公开号:US20100041717A1
    公开(公告)日:2010-02-18
    Compounds of formula (Ia) and (Ib), wherein A, B, C, R 1 and R 14 are described herein.
    式(Ia)和(Ib)的化合物,其中A、B、C、R1和R14如本文所述。
  • Novel adenine compound and use thereof
    申请人:Isobe Yoshiaki
    公开号:US20060052403A1
    公开(公告)日:2006-03-09
    A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X 1 represents oxygen, sulfur, NR 1 (R 1 represents hydrogen or alkyl), or a single bond; Y 1 represents a single bond, alkylene, etc.; Y 2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q 1 and Q 2 represents —COOR 10 (wherein R 10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.
    一种适用于局部给药的药物,作为抗过敏剂有效。该药物含有一种腺嘌呤化合物作为活性成分,该化合物由通式(1)表示:[其中环A表示6-10个成员、单环或双环、芳香烃或含有1-3个杂原子(选自0-2个氮原子、0或1个氧原子和0或1个硫原子)的5-10个成员、单环或双环、芳香杂环;n为0-2的整数;m为0-2的整数;R表示卤素、(未)取代的烷基等;X1表示氧、硫、NR1(R1表示氢或烷基)或单键;Y1表示单键、亚烷基等;Y2表示单键、亚烷基等;Z表示亚烷基;Q1和Q2中至少一个表示—COOR10(其中R10表示(未)取代的烷基等),等等]或该化合物的药学上可接受的盐。
  • FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS
    申请人:Hangeland Jon J.
    公开号:US20090036438A1
    公开(公告)日:2009-02-05
    The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R 3 , R 4 , R 6 , R 11 , X 1 , X 2 , and X 3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.
    本发明提供了一种治疗血栓性或炎症性疾病的方法,该方法向需要治疗的患者施用至少一种公式(I)或公式(V)中的化合物的治疗有效量:或其立体异构体或药学上可接受的盐或溶剂形式,其中变量A、L、Z、R3、R4、R6、R11、X1、X2和X3如本文所定义。公式(I)的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂;例如凝血酶、因子Xa、因子XIa、因子IXa、因子VIIa和/或血浆激肽。特别是,涉及到选择性因子XIa抑制剂的化合物。本发明还提供了公式I范围内的化合物,并涉及包含这些化合物的制药组合物。
  • NOVEL ADENINE COMPOUND AND USE THEREOF
    申请人:ISOBE Yoshiaki
    公开号:US20120178743A1
    公开(公告)日:2012-07-12
    An antiallergic agent for topical administration containing an adenine compound of general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X 1 represents oxygen, sulfur, NR 1 (R 1 represents hydrogen or alkyl), or a single bond; Y 1 represents a single bond, alkylene, etc.; Y 2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q 1 and Q 2 represents —COOR 10 (wherein R 10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.
    一种用于局部给药的抗过敏剂,包含一种通式(1)的腺嘌呤化合物:[其中环A代表一个6到10个成员的单环或双环芳香烃或一个5到10个成员的单环或双环芳香杂环,其中包含1到3个杂原子,选择自0到2个氮原子,0或1个氧原子和0或1个硫原子;n是0到2的整数;m是0到2的整数;R代表卤素,(未)取代的烷基等;X1代表氧,硫,NR1(R1代表氢或烷基)或单键;Y1代表单键,亚烷基等;Y2代表单键,亚烷基等;Z代表亚烷基;且Q1和Q2中的至少一个代表—COOR10(其中R10代表(未)取代的烷基等),等的药学上可接受的盐。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐